Sentence examples for mbc I from inspiring English sources

Patients with de novo HER2-positive MBC were defined as those with ≤90 days between the initial diagnosis of early-stage breast cancer and the diagnosis of MBC (i.e., they likely had occult metastatic disease at the time of initial diagnosis).

Through the REU and conversations with Professor Gergel-Hackett at MBC, I became familiar with some materials and device topics.

The MBCs (i.e., the lowest concentrations of antibacterial agents required to kill a particular bacterium) were determined by subculturing aliquots (20  μL) from wells with no visible bacterial growth and from control wells of MIC determination onto substance-free Mueller-Hinton agar (MHA) plates.

Quantitative variables were converted into three classes of qualitative variable using the following distribution of the post-MBC test fall of FEV1, i.e. MBC+ 20% (26 highest values of fall and higher than 20%), MBC+ 15% (33 next highest values and higher than 15%) and no fall (371 last values).

As a starting point, we used a PopPK model previously developed in a population predominantly composed of patients with MBC, who received i.v. trastuzumab.

Based on these promising early-phase clinical data in HER2-positive MBC, phase-III trials of trastuzumab/paclitaxel±everolimus in the first-line setting (BOLERO-1; NCT00876395) and trastuzumab/vinorelbine±everolimus in the trastuzumab-refractory setting (BOLERO-3; NCT01007942) are in progress.

The pre-progressed and the post-progressed utility values were derived from the study of Lloyd et al. [ 26], as used in several technology appraisals for mBC submitted to NICE (i.e. FULV, eribulin, lapatinib and trastuzumab) [ 15].

Docetaxel monotherapy (60 100 mg m−2, i.v., Q21D), a preferred first-line therapy for recurrent and metastatic breast cancer (MBC), often results in grade 3 or 4 neutropenia (Montero et al, 2005).

Evidence for the efficacy of lapatinib in MBC derives from Phase I III trials of monotherapy and concurrent administration of lapatinib with cytotoxic chemotherapy, other targeted treatments or endocrine agents.

Indibulin has activity against a wide range of tumor cell lines, including cells resistant to taxanes, vinca alkaloids, and anthracyclines [ 66] and is under evaluation in a phase I/II trial in MBC.

Interestingly, the recent report from the MD Anderson Cancer Centre showed that patients with MBC referred to their Phase I unit tend to be heavily pretreated and have shorter survival times compared with a broader range of advanced cancers (Wheler et al, 2009).